These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Listed as ongoing, but also has a completion date and reported results 2004-000327-15 A Phase 3 Multicenter, Open-label, Randomized Study of XL119 Versus 5-Fluorouracil (5-FU) plus Leucovorin (LV) in Subjects with Advanced Biliary Tumors Not Amenable to Conventional Surgery 2006-12-06 bad-data
Reported results 2005-000137-37 Single Dose, Randomized, Double-Blind, Parallel Group, Multicenter Study of Palonosetron 0.25 mg, 0.50 mg and 0.75 mg Administered by the Oral Route versus Palonosetron 0.25 mg IV for the Prevention o... 2006-08-31 due-trials
Reported results 2005-000298-23 A Randomized, Double-blind, Multicenter, Parallel Group, Balanced, Stratified Phase 3 Study to Evaluate the Efficacy and the Safety of Single IV Doses of Palonosetron 0.025 mg, 0.050 mg, and 0.075 mg ... 2006-05-03 due-trials
Not reported 2005-000583-28 Efficacy and tolerability of nimesulide for the treatment of migraine attacks, a randomised, double blind, placebo controlled cross-over trial 2007-01-07 due-trials
Reported results 2005-001944-21 Multicenter, Phase III, Open-Label, Uncontrolled Study to Assess the Safety and Efficacy of a Single Oral Dose of Palonosetron 0.75 mg in the Prevention of Chemotherapy Induced Nausea and Vomiting in ... 2006-04-27 due-trials
Ongoing, reported early 2005-002641-39 Open-Label Pilot Study to Evaluate the Efficacy of Palonosetron Associated with Aprepitant (Emend) and Dexamethasone in Preventing Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy (HEC) not-yet-due
Reported results 2005-002643-89 Double-blind study to compare the efficacy of palonosetron with or without the use of dexamethasone on days 2 and 3, in the prevention of nausea and vomiting induced by moderately emetogenic chemother... 2008-04-01 due-trials
Listed as ongoing, but also has a completion date 2008-003190-41 A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Prospective Study to Assess the Efficacy, Safety and Tolerability of Three Oral Doses of Netupitant Given Once a Day (50, ... 2010-05-06 bad-data
Reported results 2008-007827-14 Multicenter, Phase IV, Open-Label, Uncontrolled Study to Assess the Efficacy and Safety of a Single Intravenous Dose of Palonosetron 0.25 mg (Aloxi, Onicit, Paloxi) in the Prevention of Chemotherapy-I... 2011-04-30 due-trials
Reported results 2009-016775-30 A phase III multicenter, randomized, double-blind, double-dummy, active-controlled, parallel group study of the efficacy and safety of oral netupitant administered in combination with palonosetron and... 2012-11-06 due-trials
Reported results 2010-022223-29 Single-dose, multicenter, randomized, double-blind, double-dummy, parallel group study to assess the efficacy and safety of oral palonosetron 0.50 mg compared to I.V. palonosetron 0.25 mg administere... 2012-11-14 due-trials
Listed as ongoing, but also has a completion date and reported results 2010-022872-30 A multicenter, randomized, double-blind, parallel group study to evaluate the efficacy and safety of two different doses of palonosetron compared to ondansetron in the prevention of CINV in pediatric ... 2012-10-25 bad-data
Reported results 2010-022971-79 A Multicenter, Double-blind, Double-dummy, Randomized, Parallel Group, Stratified Study to Evaluate the Efficacy and Safety of a Single IV Dose of Palonosetron Compared to a Single IV Dose of Ondanset... 2012-03-27 due-trials
Reported results 2010-023297-39 A phase III, multicenter, randomized, double-blind, unbalanced (3:1) active control study to assess the safety and describe the efficacy of netupitant and palonosetron for the prevention of chemothera... 2012-09-13 due-trials
Reported results 2010-023648-34 Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer – Cachexia (NSCLC-C): A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study to Evaluate the Safety and Efficacy of ... 2014-10-22 due-trials
Reported results 2010-023649-31 Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer – Cachexia (NSCLC-C): A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study to Evaluate the Safety and Efficacy of ... 2014-10-10 due-trials
Reported results 2010-023650-36 Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer – Cachexia (NSCLC-C): An Extension Study (ROMANA-3) 2014-06-12 due-trials
Reported results 2011-004981-13 Phase II, Double-blind, Randomized, Two-stage, Placebo-controlled Proof of Concept Study in Colorectal Cancer Patients Receiving 5-FU-based Chemotherapy to Assess the Efficacy of Elsiglutide (ZP1846) ... 2013-01-11 due-trials
Reported results 2014-000998-39 Randomized, double-blind, parallel group, placebo-controlled, dose finding study in colorectal cancer patients receiving 5-FU-based chemotherapy to assess the efficacy of different doses of s.c. elsig... 2016-02-09 due-trials
Reported results 2015-001747-37 A phase 3, single-dose, multicenter, randomized, double-blind, parallel group study to assess the efficacy and safety of palonosetron 0.25 mg administered as a 30-minute IV infusion compared to palono... 2016-03-09 due-trials
Reported results 2015-001800-74 A phase 3, multicenter, randomized, double-blind, active control study to evaluate the safety and efficacy of IV pro-netupitant/palonosetron (260 mg/0.25 mg) combination for the prevention of chemothe... 2016-08-02 due-trials
Ongoing 2016-004724-34 A Phase III, Double-Blind, Placebo-Controlled, Multicenter, Randomized Study Of Pracinostat In Combination With Azacitidine In Patients ≥18 Years With Newly Diagnosed Acute Myeloid Leukemia Unfit For ... not-yet-due
Ongoing 2018-002926-22 A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in a... not-yet-due
Ongoing 2018-002927-40 A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in a... not-yet-due